Guidance for modifying the definition of diseases: A checklist

JAMA Internal Medicine

Volumn 177, Issue 7, 2017, Pages 1020-1025

  Doust, Jenny ^a   Vandvik, Per O ^b   Qaseem, Amir ^c   Mustafa, Reem A ^d   Horvath, Andrea R ^e   Frances, Allen ^f   Al Ansary, Lubna ^g   Bossuyt, Patrick ^h   Ward, Robyn L ⁱ   Kopp, Ina ^j   Gollogly, Laragh ^k   Schunemann, Holger ^d   Glasziou, Paul ^a  

^a BOND UNIVERSITY   (Australia)

^b INNLANDET HOSPITAL TRUST   (Norway)

^c AMERICAN COLLEGE OF PHYSICIANS   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f DUKE UNIVERSITY   (United States)

^g KING SAUD UNIVERSITY   (Saudi Arabia)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHECKLIST; DELPHI STUDY; DISEASE CLASSIFICATION; DISEASES; FEEDBACK SYSTEM; HUMAN; INCIDENCE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MEASUREMENT REPEATABILITY; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL TERMINOLOGY; PANEL STUDY; PATIENT HARM; PILOT STUDY; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; RISK BENEFIT ANALYSIS; VALIDATION STUDY; WORLD HEALTH ORGANIZATION; CLINICAL MEDICINE; CURRENT PROCEDURAL TERMINOLOGY; DISEASE MANAGEMENT; NOMENCLATURE; PROCEDURES;

CHECKLIST; CLINICAL MEDICINE; CURRENT PROCEDURAL TERMINOLOGY; DISEASE; DISEASE MANAGEMENT; GUIDELINES AS TOPIC; HUMANS; TERMINOLOGY AS TOPIC;

EID: 85024477388     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2017.1302     Document Type: Review

References (38)

1. Carter SM, Rogers W, Heath I, Degeling C, Doust J, Barratt A. The challenge of overdiagnosis begins with its definition. BMJ. 2015;350:h869.
2. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: howto stop harming the healthy. BMJ. 2012;344:e3502.
3. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ. 1995; 311(7016):1356-1359.
4. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
5. Sundström J, Arima H,Woodward M, et al; Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: ameta-analysis of individual patient data. Lancet. 2014;384(9943): 591-598.
6. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013;10(8):e1001500.
7. Donaldson MG, Cawthon PM, Lui LY, et al; Study of Osteoporotic Fractures. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines. J Bone Miner Res. 2009;24(4):675-680.
8. Roger VL, Killian JM,Weston SA, et al. Redefinition ofmyocardial infarction: prospective evaluation in the community. Circulation. 2006;114 (8):790-797.
9. Zhuang J, Liu Y, Xu L, et al. Prevalence of the polycystic ovary syndrome in female residents of Chengdu, China. Gynecol Obstet Invest. 2014;77(4): 217-223.
10. Xu Y,Wang L, He J, et al; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948-959.
11. James C, Bullard KM, Rolka DB, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care. 2011;34(2):387-391.
12. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. National Academies Press;Washington, DC. 2011.
13. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P; Board of Trustees of the Guidelines International Network. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156(7):525-531.
14. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7(2):e1000217.
15. Glasziou P, Irwig L, Deeks JJ. When should a new test become the current reference standard? Ann Intern Med. 2008;149(11):816-822.
16. Schwartz LM,Woloshin S. Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988-1994. Eff Clin Pract. 1999;2(2):76-85.
17. Tunstall-Pedoe H. Comment on the ESC/ACC redefinition ofmyocardial infarction by a consensus dissenter. Eur Heart J. 2001;22(7):613-616.
18. Gerber A, Hentzelt F, Lauterbach KW. Can evidence-based medicine implicitly rely on current concepts of disease or does it have to develop its own definition? J Med Ethics. 2007;33(7):394-399.
19. Lahey BB, Applegate B, McBurnett K, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. AmJ Psychiatry. 1994;151(11):1673-1685.
20. Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J AmAcad Child Adolesc Psychiatry. 2014;53(1):34-46.e2.
21. Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015; 350:h870.
22. Liew SM, Doust J, Glasziou P. Cardiovascular risk scores do not account for the effect of treatment: a review. Heart. 2011;97(9):689-697.
23. Lijmer JG, Bossuyt PM. Diagnostic testing and prognosis: the randomised controlled trial in diagnostic research. In: Knottnerus A, ed. Evidence base of clinical diagnosi. Blackwell Pub;Oxford, United Kingdom. 2002.
24. Yudkin JS, Montori VM. The epidemic of pre-diabetes: the medicine and the politics. BMJ. 2014;349:g4485.
25. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.
26. Beko G, Butz H, Berta K, et al. Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy. Clin Chem Lab Med. 2013;51(6):1251-1256.
27. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-1588.
28. Zeidler H. The need to better classify and diagnose early and very early rheumatoid arthritis. J Rheumatol. 2012;39(2):212-217.
29. Ioannidis JP, Tzoulaki I. What makes a good predictor? the evidence applied to coronary artery calcium score. JAMA. 2010;303(16):1646-1647.
30. Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist. 2007;12(3): 301-311.
31. Loke YK, Price D, Herxheimer A; Cochrane Adverse EffectsMethods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med ResMethodol. 2007;7:32.
32. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
33. Norwegian Directorate of Health working group on national clinical practice guidelines for gestational diabetes 2016. https://helsedirektoratet.no/retningslinjer/diabetes. Accessed March 6, 2017.
34. Thomas R, Mitchell GK, Batstra L. Attention-deficit/hyperactivity disorder: are we helping or harming? BMJ. 2013;347:f6172.
35. Heath I.Waste and harm in the treatment of mild hypertension. JAMA Intern Med. 2013;173(11): 956-957.
36. Albert MS, De Kosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 270-279.
37. Aronowitz RA. The converged experience of risk and disease. Milbank Q. 2009;87(2):417-442.
38. Schwartz PH. Risk and disease. Perspect Biol Med. 2008;51(3):320-334.